NICE compared 19 different wound care treatments to standard of care and Epifix didn't participate, why? Grafix received the only and highest ranking from NICE.
Boa scoty-scam, what are you writing about your one product - Epifix (low quality) - company MiMedx against Osiris?
Yes, time will tell!!
..the National Institute for health and care excellence (GB) in August 2015 rated Grafix therapy with the mention HIGH QUALITY while Amniotic Memory wound graft (Epifix) was rated LOW QUALITIY.
Sentiment: Strong Buy
Recent Osiris Therapeutics Inc Analyst Ratings
Out of 8 analysts covering Osiris Therapeutics, 4 rate it “Buy”, 1 “Sell”, while 3 “Hold”. This means 50% of Osiris Therapeutics’s analysts are positive. $31 is the highest target while $13 is the lowest. The stock has $21.80 average target or 112.06% above today’s ($10.28) stock price. OSIR was the topic in 20 analyst reports since December 29, 2014 according to StockzIntelligence Inc. Brean Capital downgraded Osiris Therapeutics’s stock on November 17 to “Sell” rating. Chardan Capital Markets initiated it with “Neutral” rating and $13 target price in a November 2 report. Goldman Sachs initiated the shares of Osiris Therapeutics in a report on November 16 with “Buy” rating. Zacks upgraded OSIR’s stock on May 20. Zacks has “Buy” rating and $20 price target. Finally, TH Capital initiated the shares of Osiris Therapeutics with “Buy” rating in a November 6 report.
Merger with Mesoblast, no, but with Celgene
- Corporate pipeline, with
-Peripheral artery disease/Diabetic foot ulcers